These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 15675210)

  • 1. Safe duration of postoperative monitoring for malignant hyperthermia susceptible patients.
    Pollock N; Langtont E; Stowell K; Simpson C; McDonnell N
    Anaesth Intensive Care; 2004 Aug; 32(4):502-9. PubMed ID: 15675210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safe duration of postoperative monitoring for malignant hyperthermia patients administered non-triggering anaesthesia: an update.
    Barnes C; Stowell KM; Bulger T; Langton E; Pollock N
    Anaesth Intensive Care; 2015 Jan; 43(1):98-104. PubMed ID: 25579296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy.
    Carr AS; Lerman J; Cunliffe M; McLeod ME; Britt BA
    Can J Anaesth; 1995 Apr; 42(4):281-6. PubMed ID: 7788824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of anaesthesia in patients suspected to be susceptible to malignant hyperthermia before diagnostic in vitro contracture test.
    Bendixen D; Skovgaard LT; Ording H
    Acta Anaesthesiol Scand; 1997 Apr; 41(4):480-4. PubMed ID: 9150775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant hyperthermia and day stay surgery.
    Pollock N; Langton E; McDonnell N; Tiemessen J; Stowell K
    Anaesth Intensive Care; 2006 Feb; 34(1):40-5. PubMed ID: 16494148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence of malignant hyperthermia in patients administered triggering agents before malignant hyperthermia susceptibility identified: missed opportunities prior to diagnosis.
    Chan TY; Bulger TF; Stowell KM; Gillies RL; Langton EE; Street NE; Pollock NA
    Anaesth Intensive Care; 2017 Nov; 45(6):707-713. PubMed ID: 29137581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of vecuronium and doxapram in patients susceptible to malignant hyperthermia.
    Ording H; Fonsmark L
    Br J Anaesth; 1988 Mar; 60(4):445-9. PubMed ID: 2895665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States.
    Larach MG; Brandom BW; Allen GC; Gronert GA; Lehman EB
    Anesth Analg; 2014 Dec; 119(6):1359-66. PubMed ID: 25268394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
    Mortier W; Breucking E
    Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia.
    Sato N; Brum JM; Mitsumoto H; DeBoer GE
    Can J Anaesth; 1995 Feb; 42(2):158-62. PubMed ID: 7720160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of 119 anaesthetics received after investigation for susceptibility to malignant hyperthermia.
    Ording H; Hedengran AM; Skovgaard LT
    Acta Anaesthesiol Scand; 1991 Nov; 35(8):711-6. PubMed ID: 1763590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Malignant hyperthermia--diagnostics, treatment and anaesthetic management].
    Schuster F; Müller-Reible CR
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2009 Nov; 44(11-12):758-63; quiz 764. PubMed ID: 19918708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of anaesthetics received by patients before susceptibility to malignant hyperpyrexia was recognized.
    Halsall PJ; Cain PA; Ellis FR
    Br J Anaesth; 1979 Oct; 51(10):949-54. PubMed ID: 518796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscle biopsy for malignant hyperthermia screening in children.
    Ummenhofer W; Roesslein R; Sutter PM; Moser N; Kern C; Urwyler A
    Eur J Pediatr Surg; 1997 Oct; 7(5):259-62. PubMed ID: 9402480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of malignant hyperthermia susceptibility: statistical evaluation of clinical signs.
    Hackl W; Mauritz W; Schemper M; Winkler M; Sporn P; Steinbereithner K
    Br J Anaesth; 1990 Apr; 64(4):425-9. PubMed ID: 2334615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follow-up of patients tested for malignant hyperthermia susceptibility.
    Scala D; Di Martino A; Cozzolino S; Mancini A; Bracco A; Andria B; Tammaro A; Savoia G
    Eur J Anaesthesiol; 2006 Sep; 23(9):801-5. PubMed ID: 16780615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between known or strongly suspected malignant hyperthermia susceptibility and postoperative outcomes: an observational population-based study.
    Jones PM; Allen BN; Cherry RA; Dubois L; Vogt KN; Shariff SZ; Bray Jenkyn KM; Riazi S; Wijeysundera DN
    Can J Anaesth; 2019 Feb; 66(2):161-181. PubMed ID: 30421146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant Hyperthermia Susceptibility and Fitness for Duty.
    Lee MA; McGlinch EB; McGlinch MC; Capacchione JF
    Mil Med; 2017 Mar; 182(3):e1854-e1857. PubMed ID: 28290972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of malignant hyperthermia episodes with the Clinical Grading Scale].
    von Richthofen V; Wappler F; Scholz J; Fiege M; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Apr; 33(4):244-9. PubMed ID: 9617423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of exposure of malignant hyperthermia non-susceptible patients and their relatives to anaesthetic triggering agents.
    Pollock N; Langton EE; Stowell KM; Bulger TF
    Anaesth Intensive Care; 2011 Sep; 39(5):887-94. PubMed ID: 21970134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.